Clinical and morphological characteristics of parathyroid carcinoma

Close metadata

Recommended articles:

The role of immunohistochemical examination in the differential diagnosis of atypical tumors and carcinomas of parathyroid glands. Russian Journal of Archive of Pathology. 2024;(4):5-12

Features of the bone metabolism in primary hyperparathyroidism. Russian Journal of Preventive Medicine. 2024;(9):130-137

Economic issues of medical care for hyperparathyroidism. Part 1. Primary hyperparathyroidism. Medical Technologies. Assessment and Choice. 2025;(1):51-61

Health care for patients suffered from hyperparathyroidism: data from the Federal Compulsory Medical Insurance Fund. Russian Journal of Preventive Medicine. 2025;(6):33-40

Parathyroid carcinoma (PTC) is a rare malignant tumor with the clinical manifestation of hyperparathyroidism, reliable morphological signs of invasive growth, and poor clinical prognosis. The differential diagnosis of PTC due to the rarity of this pathology, not always explicit morphological criteria, and the lack of a certain immunohistochemical panel is complex and needs further clarification. The paper summarizes an update on the clinical and morphological characteristics of PTC.

Keywords:

parathyroid carcinoma

atypical adenoma

primary hyperparathyroidism

HRPT2 protein

parafibromin

CDC73 gene mutations

Authors:

Voronkova I.A.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Mokrysheva N.G.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Kazantseva I.A.

M.F. Vladimirsky Moscow Regional Research Clinical Institute

Gurevich L.E.

GU Moskovskiĭ oblastnoĭ nauchno-issledovatel'skiĭ klinicheskiĭ institut im. M.F. Vladimirskogo

List of references:

Favia G, Lumachi F, Polistina F, D’Amico DF. Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg. 1998;22(12):1225-1230.
Shane E. Clinical review 122 parathyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):485-492.
Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, Haigh PI, Adams AL. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98(3):1122-1129. https://doi.org/10.1210/jc.2012-4022
Mokrysheva NG, Rozhinskaya LYa, Peretokina EV, Rostomyan LG, Mirnaya SS, Pronin VS, Markina NV, Shebesheva EN, Antsiferov MB, Dedov II. The results of analysis of the major epidemiological characteristics of primary hyperparathyroidism in Russia based on the registry data. Problemy endokrinologii. 2012;58(5):16-20. (In Russ.) https://doi.org/10.14341/probl201258516-20
Miki H, Sumitomo M, Inoue H, Kita S, Monden Y. Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Surgery.1996;120(5):897-901.
Desch C, Arsensis G, May A, Amatruda J. Parathyroid hyperplasia and carcinoma within one gland. Am J Med. 1984;77(1):131-134.
Mamedova EO, Mokrysheva NG, Pigarova EA, Voronkova IA, Kuznetsov SN, Vasil’ev EV, Petrov VM, Kuznetsov NS, Rozhinskaya LYa, Tyul’pakov AN. Molecular and genetic features of primary hyperparathyroidism in young patients. Problemy endokrinologii. 2016;62(2):4-11. (In Russ.) https://doi.org/10.14341/probl20166224-11
Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349(18):1722-1729.
Mori H, Okada Y, Arao T, Tanaka Y. Case of parathyroid carcinoma with highly aggressive clinical course. J UOEH. 2014;36(4): 243-249. https://doi.org/10.7888/juoeh.36.243
Sundelin K, Tullgren O, Farnebo LO. Clinical corse of metastatic parathyroid cancer. World J Surg. 1994;18(4):594-598.
Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP. Parathyroid carcinoma. J Bone Miner Res. 2008; 23(12):1869-1880. https://doi.org/10.1359/jbmr.081018
Fernandez-Ranvier GG, Khanafshar E, Jensen K, Zarnegar R, Lee J, Kebebew E, Duh QY, Clark OH. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007; 110(2):255-264.
Sandelin K, Auer G, Bondeson L, Grimelius L, Farnebo LO. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16(4):724-731.
Erovic BM, Goldstein DP, Kim D, Mete O, Brierley J, Tsang R, Freeman JL, Asa SL, Rotstein L, Irish JC. Parathyroid cancer: Outcome analysis of 16 patients treated at the Princess Margaret Hospital. Head Neck. 2013;35(1):35-39. https://doi.org/10.1002/hed.22908
DeLellis RA, Arnold A, Bilezikian JP, Eng C, Larsson C, Lloyd RV, Mete O. Parathyroid carcinoma. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J, eds. WHO classification of tumours of endocrine organs. Lyon: IARC; 2017;147-152.
Bondeson L, Sandelin K, Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinomas. Am J Surg Pathol. 1993;17(8):820-829.
DeLellis RA. Parathyroid tumors and related disorders. Mod Pathol. 2011; 24(2):78-93. https://doi.org/10.1038/modpathol.2010.132
Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86(3):538-544.
Chantz A, Castlema B. Parathyroid carcinoma. A study of 70 cases. Cancer. 1973;31(3):600-605.
Duan K, Mete Ö. Parathyroid carcinoma: diagnosis and clinical implications. Turk Patoloji Derg. 2015;31:80-97. https://doi.org/10.5146/tjpath.2015.01316
Elgoweini M, Chetty R. Hyalinizing parathyroid adenoma and hyperplasia: Report of 3 cases of an unusual histologic variant. Ann Diagn Pathol. 2011;15(5):329-332. https://doi.org/10.1016/j.anndiagpath.2011.03.001
Alwaheeb S, Rambaldini G, Boerner S, Coiré C, Fiser J, Asa SL. Worrisome histologic alterations following fine-needle aspiration of the parathyroid. J Clin Oncol. 2006;59(10):1094-1096. https://doi.org/10.1136/jcp.2005.029017
Wynne A, van Heerden J, Carney J, Fitzpatrick L. Parathyroid carcinoma: clinical and pathological features in 43 patients. Medicine (Baltimore). 1992;71(4):197-205.
Wang O, Wang C, Nie M, Cui Q, Guan H, Jiang Y, Li M, Xia W, Meng X, Xing X. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas. PLoS One. 2012;7(9):e45567. https://doi.org/10.1371/journal.pone.0045567
Simonds WF. Parathyroid cancer and the CDC73 tumor suppressor gene. Int J Endocr Oncol. 2014;1(1):59-69. https://doi.org/10.2217/ije.14.2
Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A, Marcocci C. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol. 2007;156(5):547-554. https://doi.org/10.1530/EJE-06-0720
Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349(18):1722-1729.
Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, Cianferotti L, Ambrogini E, Gazzerro E, Colussi G, Berti P, Miccoli P, Pinchera A, Marcocci C. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: Germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 2004;89(11):5583-5591.
Hosny Mohammed K, Siddiqui MT, Willis BC, Zaharieva Tsvetkova D, Mohamed A, Patel S, Sharma J, Weber C, Cohen C. Parafibromin, APC, and MIB-1 are useful markers for distinguishing parathyroid carcinomas from adenomas. Appl Immunohistochem Mol Morphol. 2017;25(10):731-735. https://doi.org/10.1097/PAI.0000000000000378
Lumachi F, Ermani M, Marino F, Iacobone M, Baldessin M, Cappuzzo G, Zanella S, Favia G. PCNA-LII, Ki-67 immunostaining, p53 activity and histopathological variables in predicting the clinical outcome in patients with parathyroid carcinoma. Anticancer Res. 2006;26(2A):1305-1308.
Hu Y, Liao Q, Cao S, Gao X, Zhao Y. Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a metaanalysis. Endocrine. 2016;54(3):612-619. https://doi.org/10.1007/s12020-016-0997-3
Kruijff S, Sidhu SB, Sywak MS, Gill AJ, Delbridge LW. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas. Ann Surg Oncol. 2014;21(2):426-433. https://doi.org/10.1245/s10434-013-3288-8
Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, Clark OH. Defining a molecular phenotype for benign and malignant parathyroid tumours. Cancer. 2009;115(2): 334-344. https://doi.org/10.1002/cncr.24037
Cakir B, Polat SB, Kilic M, Ozdemir D, Aydin C, Süngü N, Ersoy R. Evaluation of preoperative ultrasonographic and biochemical features of patients with aggressive parathyroid disease: is there a reliable predictive marker? Arch Endocrinol Metab. 2016; 60(6):537-544. https://doi.org/10.1590/2359-3997000000224
DeLellis RA, Arnold A, Eng C, Erickson LA, Franssila KO, Haigh PI, Hendy GN, Hunt JL. Parathyroid adenoma. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J, eds. WHO classification of tumours of endocrine organs. Lyon: IARC; 2017;153-158.
Stojadinovic A, Hoos A, Nissan A, Dudas ME, Cordon-Cardo C, Shaha AR, Brennan MF, Singh B, Ghossein RA. Parathyroid neoplasms: clinical, histopathologic and tissue microarray - based molecular analysis. Hum Pathol. 2003;34(1):54-64.
Kandil E, Noureldine S, Khalek MA, Daroca P, Friedlander P. Ectopic secretion of parathyroid hormone in a neuroendocrine tumor: a case report and review of the literature. Int J Clin Exp Med. 2011;4(3):234-240.
Landry CS, Wang TS, Asare EA, Grogan RH, Hunt JL, Ridge JA, Rohren E, Shah JP, Subramaniam RM, Brierley JD, Seethala RR, Perrier ND. Parathyroid. 8th ed. AJCC Cancer Staging Manual. 2017 Springer;ch75:903-910. https://doi.org/10.1007/978-3-319-40618-3_75

Close metadata